Strontium Ranelate |
Formulary
|
Granules 2g/sachet Treatment of severe osteoporosis - in postmenopausal women; - in adult men at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. In postmenopausal women, strontium ranelate reduces the risk of vertebral and hip fractures. The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks |
MHRA: Strontium: cardiovascular risk—restricted indication and new monitoring requirements |
|